The Europe Anxiety Disorders And Depression Treatment Market is projected to witness market growth of 3.1% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Anxiety Disorders And Depression Treatment Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.02 billion by 2031. The UK market is exhibiting a CAGR of 2.3% during 2024-2031. Additionally, the France market would exhibit a CAGR of 3.9% during 2024-2031.
The development of new and more effective antidepressants and anxiolytics, with improved safety profiles and fewer side effects, has expanded treatment options for patients. Adopting digital mental health solutions, including mobile therapy and mood-tracking apps, has made treatment more accessible and convenient.
Additionally, many healthcare providers now include mental health screenings as part of routine medical check-ups, which has led to early identification and intervention for anxiety and depression. Programs focusing on early intervention and preventive care have increased the adoption of treatments before conditions become severe.
The rising cases of depression and anxiety among European workers drive companies to implement or expand workplace mental health programs. This creates increased demand for mental health resources, employee assistance programs (EAPs), and counselling services designed to support affected employees. As per the European Council, in 2022, 27% of workers in Europe experienced stress, depression, or anxiety. Additionally, there was a 22% rise in loneliness across the E.U. following the COVID-19 pandemic.
Based on Indication, the market is segmented into Anxiety and Depression. Based on Drugs, the market is segmented into Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Anxiety Disorders And Depression Treatment Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.02 billion by 2031. The UK market is exhibiting a CAGR of 2.3% during 2024-2031. Additionally, the France market would exhibit a CAGR of 3.9% during 2024-2031.
The development of new and more effective antidepressants and anxiolytics, with improved safety profiles and fewer side effects, has expanded treatment options for patients. Adopting digital mental health solutions, including mobile therapy and mood-tracking apps, has made treatment more accessible and convenient.
Additionally, many healthcare providers now include mental health screenings as part of routine medical check-ups, which has led to early identification and intervention for anxiety and depression. Programs focusing on early intervention and preventive care have increased the adoption of treatments before conditions become severe.
The rising cases of depression and anxiety among European workers drive companies to implement or expand workplace mental health programs. This creates increased demand for mental health resources, employee assistance programs (EAPs), and counselling services designed to support affected employees. As per the European Council, in 2022, 27% of workers in Europe experienced stress, depression, or anxiety. Additionally, there was a 22% rise in loneliness across the E.U. following the COVID-19 pandemic.
Based on Indication, the market is segmented into Anxiety and Depression. Based on Drugs, the market is segmented into Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Pfizer Inc.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Eli Lilly And Company
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
Market Report Segmentation
By Indication
- Anxiety
- Depression
By Drugs
- Antidepressants
- Anxiolytics
- Anticonvulsants
- Noradrenergic Agents
- Atypical Antipsychotics
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Anxiety Disorders And Depression Treatment Market by Indication
Chapter 5. Europe Anxiety Disorders And Depression Treatment Market by Drugs
Chapter 6. Europe Anxiety Disorders And Depression Treatment Market by Distribution Channel
Chapter 7. Europe Anxiety Disorders And Depression Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Pfizer Inc.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Eli Lilly And Company
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
Methodology
LOADING...
